Sunday 18 October 2026
Export IMMP’s income statement to Excel — free account
Prima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.
3.20
0.01
−0.31%
Follow IMMP
| Older periods | Jun '23 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
— | 16.75 | 18.03 | 2.89 | |
Current Ratio |
— | 17.24 | 18.86 | 2.97 | |
Net Debt/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
— | 0.00% | 0.57% | 0.34% | |
Debt/Equity |
— | 0.00 | 0.01 | 0.01 | |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
— | 0.07 | 0.04 | 0.04 | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (0.01) | (18.61) | (18.87) | |
Working Capital |
— | 69.38 | 107.21 | 60.92 | |
Capital Expenditures |
— | (0.01) | (0.01) | (0.06) | |
Net Current Asset Value |
— | 68.35 | 106.79 | 60.07 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 3.61 | 4.17 | 13.91 | |
Average Payables |
— | 3.15 | 4.13 | 17.58 | |
Average Assets |
— | 55.02 | 87.36 | 92.11 | |
Average Common Equity |
— | 47.26 | 78.38 | 72.13 |
Columns are period end dates · fundamentals updated 2 Oct 2026